Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study

Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6 i), abemaciclib, palbociclib, and ribociclib, have been FDA-approved for the treatment of hormone receptor-positive (HR+), HER2−negative (HER2−) advanced breast cancer (aBC). This targeted therapy has revived hope in those aBC patients who d...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Angelo, Alberto, Giudici, Fabiola, Chapman, Robert, Darlow, Jacob, Kilili, Huseyin, Sobhani, Navid, Cinelli, Mattia, Cappelletti, Maria Rosa, Strina, Carla, Milani, Manuela, Generali, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497904/
https://www.ncbi.nlm.nih.gov/pubmed/36135204
http://dx.doi.org/10.3390/cimb44090292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497904/
https://www.ncbi.nlm.nih.gov/pubmed/36135204
http://dx.doi.org/10.3390/cimb44090292

Ejemplares similares